RecruitingPhase 1Phase 2NCT06874010

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Patients With Friedreich's Ataxia

Sponsor

Design Therapeutics, Inc.

Enrollment

20 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Friedreich Ataxia

Summary

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DT-216P2 for people with friedreich ataxia. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.